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Available online 3 May 2017Aims:We questioned whether aldosterone and oxidative stress play a role in vascular damage in severe hyper-
tension and investigated the role of Nox1 in this process.
Materials and methods:We studied mesenteric arteries, aortas and vascular smooth muscle cells (VSMC) from
WKY and SHRSP rats. Vascular effects of eplerenone or canrenoic acid (CA) (mineralocorticoid receptor (MR)
blockers), ML171 (Nox1 inhibitor) and EHT1864 (Rac1/2 inhibitor) were assessed. Nox1-knockout mice were
also studied. Vessels andVSMCswere probed for Noxs, reactive oxygen species (ROS) and pro-ﬁbrotic/inﬂamma-
tory signaling.
Key ﬁndings: Blood pressure and plasma levels of aldosterone and galectin-3 were increased in SHRSP versus
WKY. Acetylcholine-induced vasorelaxation was decreased (61% vs 115%) and phenylephrine-induced contrac-
tion increased in SHRSP versus WKY (Emax 132.8% vs 96.9%, p b 0.05). Eplerenone, ML171 and EHT1864 attenu-
ated hypercontractility in SHRSP. Vascular expression of collagen, ﬁbronectin, TGFβ, MCP-1, RANTES, MMP2,
MMP9 and p66Shcwas increased in SHRSP versusWKY. These changes were associatedwith increased ROS gen-
eration, 3-nitrotyrosine expression and Nox1 upregulation. Activation of vascular p66Shc and increased expres-
sion of Nox1 and collagen I were prevented by CA in SHRSP. Nox1 expression was increased in aldosterone-
stimulatedWKYVSMCs, an effect thatwas ampliﬁed in SHRSP VSMCs (5.2vs9.9 fold-increase).ML171 prevented
aldosterone-induced VSMC Nox1-ROS production. Aldosterone increased vascular expression of ﬁbronectin and
PAI-1 in wild-type mice but not in Nox1-knockout mice.
Signiﬁcance: Our ﬁndings suggest that aldosterone, which is increased in SHRSP, induces vascular damage
through MR-Nox1-p66Shc-mediated processes that modulate pro-ﬁbrotic and pro-inﬂammatory signaling
pathways.ndMedical S
d Kingdom
yz).
. This is an o© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Hypertension-associated vascular damage is characterised by func-
tional, structural and mechanical alterations comprising
hypercontractility, endothelial dysfunction, inﬂammation, calciﬁcation
and ﬁbrosis [1,2]. Molecular mechanisms underlying vascular changes
in hypertension are incompletely understood, but a role for the miner-
alocorticoid hormone aldosterone, has been suggested. Aldosterone
acts through genomic and non-genomic pathways to regulate blood
pressure and electrolytic homeostasis. Accumulating evidence suggestsciences, University
pen access article underthat aldosterone also has direct vascular effects and that it is a potent
pro-ﬁbrotic agent in cardiovascular remodeling in hypertension [3]. Ev-
idence from animal models and clinical trials in patients with heart fail-
ure demonstrate that blockade of the mineralocorticoid receptor (MR)
through which aldosterone signals, is cardio- and vaso-protective [4,
5]. In the context of vascular function, a role for aldosterone-MR signal-
ing remains controversial because aldosterone has been shown to in-
duce both vasorelaxation and vasoconstriction [6]. Recently, a role for
reactive oxygen species (ROS) has been suggested tomediate the detri-
mental effects of aldosterone in the vasculature [3].
Oxidative stress has been strongly implicated in many of the molec-
ular processes associated with endothelial dysfunction, structural re-
modeling and vascular inﬂammation in hypertension [7–9]. In the
vascular wall, NADPH oxidases (Noxs) are the predominant source of
ROS and are upregulated in hypertension [7–9]. Nox isoforms 1,2,4the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primers targeted to rat genes for qRT-PCR analysis.
Rat gene Forward primer Reverse primer
Nox1 TCCCTTTGCTTCCTTCTTGA CCAGCCAGTGAGGAAGAGTC
NoxA1 TTACTGTGCCCCTGAAGGTC CTCGGGCTTTGTAGCTGAAC
NoxO1 TCCAGACGTTTGCCTTCTCT CGTGTCAACAATGGAGCATC
Nox2 ACCCTTTCACCCTGACCTCT TCCCAGCTCCCACTAACATC
Nox4 CCAGAATGAGGATCCCAGAA AGCAGCAGCAGCATGTAGAA
P22phox TTGTTGCAGGAGTGCTCATC CAGGGACAGCAGTAAGTGGA
P47phox AGCTCCCAGGTGGTATGATG ATCTTTGGCCGTCAGGTATG
MMP2 AGCTCCCGGAAAAGATTGAT TCCAGTTAAAGGCAGCGTCT
MMP9 CACTGTAACTGGGGGCAACT CACTTCTTGTCAGCGTCGAA
MCP-1 CAGTTAATGCCCCACTCACC TTCCTTATTGGGGTCAGCAC
RANTES ATATGGCTCGGACACCACTC CCACTTCTTCTCTGGGTTGG
18S AAGTCCCTGCCGTTTGTACACA GATCCGAGGGCCTCACTAAAC
111A.P. Harvey et al. / Life Sciences 179 (2017) 110–119and 5 are expressed in human vascular tissue and appear to be dysreg-
ulated in pathological conditions [8–10]. Increased activation of Nox1,
Nox2 and Nox5 has been demonstrated in hypertension-associated car-
diovascular damage, whereas Nox4 activation has been associated with
both beneﬁcial [11,12] and injurious effects [13].
A key role for Nox1 in redox signaling in angiotensin II (AngII)-de-
pendent models of hypertension has been demonstrated [14]. Nox1
has also been shown to be linked to AngII and aldosterone signaling in
vascular cells [15–17]. However, the relationship between aldosterone
and Nox1 in the context of vascular remodeling in hypertension is in-
completely deﬁned.
The stroke-prone spontaneously hypertensive rat (SHRSP) repre-
sents a robust model of human hypertension with end-organ damage.
In this model, upregulation of Nox1 has been observed [18] and inhibi-
tion of aldosterone signaling is associated with beneﬁcial results [19]. Ita
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Fig. 1. Assessment of vascular contraction to phenylephrine (PE) (a) and endothelial-dependen
curve (c) and wall to lumen ratio (d) assessed by pressure myography in WKY and SHRSP ratshas yet to be determined whether aldosterone mediates its effects
through activation of Noxs. Here we hypothesise that in SHRSP rats, al-
dosterone promotes vascular damage through mechanisms involving
Nox1.
2. Methods
2.1. Experimental animals
Animal experiments were performed in accordance with the United
Kingdom Animals Scientiﬁc Procedures Act 1986 and ARRIVE Guide-
lines [20] and approved by the institutional ethics review committee.
Male WKY and SHRSP rats aged at 16–18 weeks were used for experi-
mentation. In additional studies rats were treated with canrenoic acid
(CA) (10 mg/kg/day, in drinking water) from weaning until 18 weeks
old. Male Nox1 knockout mice (Nox1-/y) aged 10–12 weeks were in-
fusedwith aldosterone (3× 10−4mol/L/Kg/day) for 4weeks by osmotic
minipumps (model 2004, Alzet, Cupertino, CA) implanted under
isoﬂurane (3% induction; 1.5% maintenance) anaesthesia. Animals
were euthanized by exsanguination following cardiac puncture with
immediate dissection of tissues that were rinsed, snap-frozen in liquid
nitrogen and stored at−80 °C or ﬁxed in formalin for preparation of
histological analysis.
2.2. Blood pressure measurement
Mean arterial pressure was measured in WKY and SHRSP rats using
tail-cuff plethysmography. Rats were placed in isolation chambers on a
heated platform, and blood pressure measurements were obtained. Be-
fore recording measurements, animals were trained for 5 consecutiveb
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112 A.P. Harvey et al. / Life Sciences 179 (2017) 110–119days. Animals were initially subjected to preliminary measurements,
which were not recorded; followed by 10 recorded measurements.
Mean arterial pressure is displayed as the average of 10 measurements.
2.3. Plasma aldosterone, plasma galectin-3 and vascular nitrotyrosinemea-
surements by ELISA
Plasma aldosterone (Cayman Chemical, Ann Arbor, USA), plasma
galectin-3 (Life Technologies, Paisley, UK) and mesenteric artery
nitrotyrosine (Abcam, Cambridge, UK) levels were measured by ELISA
according to manufacturer's instructions.
2.4. Vascular smooth muscle cell isolation
Rat mesenteric arteries underwent enzymatic digestion for culture
of vascular smooth muscle cells (VSMCs) as previously described [21].
Experiments were performed on low-passage cells (passage 4–7).
Prior to experimentation, cell cultures were rendered quiescent by
serum deprivation (0.5% FBS) for 18 h.
2.5. Vascular structure and function in mesenteric arteries
Rat mesenteric arteries were cut into 2 mm ring segments and
mounted on isometric wire myographs (Danish Myo Technology, Den-
mark) ﬁlled with 5mL of physiological saline solution and continuously
gassed with a mixture of 95% O2 and 5% CO2 while maintained at a con-
stant temperature of 37± 0.5 °C. Following 60 min of equilibration, the
contractility of arterial segments was assessed by the addition of 12
× 10−2 mol/L KCl solution. The integrity of the endothelium was46810
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Fig. 2. Effects of MR blockade and Rac and Nox inhibition on hypertension-associated vasc
phenylephrine (PE) in the presence of MR blocker, eplerenone (a), Rac1/2 inhibitor, EHT186
mean ± SEM (n= 5–15 per group), *P b 0.05 WKY vehicle vs SHRSP vehicle curve; †p b 0.05veriﬁed by relaxation induced by acetylcholine (Ach; 10−5mol/L) in ar-
teries pre-contractedwith phenylephrine (PE; 10−6mol/L). In addition-
al experiments vessels were preincubated for 60min prior to the curves
with the mineralocorticoid receptor blocker, eplerenone (10−6 mol/L),
Rac1/2 inhibitor, EHT1864 (10−5 mol/L) and Nox1 inhibitor, ML171
(10−5 mol/L).
Additional segments of mesenteric artery (~4 mm long) were stud-
ied as pressurized preparations using a Pressure Myograph System
(110P system; Danish Myo Technology, Denmark) in Ca2+ free physio-
logical saline solution where intramural pressure was set to 70 mmHg
for 30min to allow vessels to equilibrate and generate a variable degree
of myogenic tone. Vessels were subjected to an increasing intramural
pressure gradient ranging from 10 to 120 mmHg at 5 min intervals.
Inner and outer vessel wall measurements were recorded and used to
calculate structural elastic properties. Statistical signiﬁcance was
assessed by non-linear regression analysis.2.6. Collagen content assessed by picrosirius red staining
To assess vascular collagen expression, portions of abdominal
aorta were ﬁxed in 10% neutral buffered formalin following excision
and parafﬁn embedding, where 5 μm sections were stained with
picrosirius red (0.1% w/v). In order to distinguish between collagen
type I and type III, stained sections were visualised and imaged
under polarised light using an Olympus BH-2 microscope (Olympus,
Japan). Data were quantiﬁed by digital image analysis (ImageJ) with
the observer blinded to sample identity and expressed as the ratio of
collagen type I to collagen type III.b
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ular hypercontractility. Assessment of vascular contraction in rat mesenteric artery to
4 (b) and Nox1 inhibitor, ML171 (c) assessed by wire myography, curves represent the
SHRSP vehicle vs SHRSP treated curve.
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Protein was extracted from cleaned and snap frozen mesenteric ar-
teries and aortas from WKY, SHRSP rats, and from cultured rat VSMCs.
Protein (30 μg) was separated by electrophoresis on a polyacrylamide
gel and transferred to a nitrocellulose membrane. Non-speciﬁc binding
sites were blocked with 5% bovine serum albumin in Tris-buffered sa-
line (TBS) solution. Membranes were then incubated with speciﬁc anti-
bodies overnight at 4 °C. Membranes were washed 3 times with TBS-
Tween 20 and incubated with speciﬁc secondary antibodies for 1 h at
room temperature. Signals were revealed after reaction with enhanced
chemiluminescence. Resultswere normalised toα-tubulin orβ-actin, as
indicated in the ﬁgures and are expressed as arbitrary units. In most of
our studies we used α-tubulin as the housekeeping protein, except for
the studies assessing p66Shc expression in aorta, where we used β-
actin as our internal control. This related to technical aspects, where
β-actin detection was superior to that of α-tubulin. Antibodies were
as follows: anti-TGFβ (SC146, Santa Cruz, USA) anti-ﬁbronectin
(F3648, Sigma-Aldrich, UK), anti-phospho-p66Shc (566,807,
Calbiochem, USA), anti-α-tubulin (AB4074, Abcam, UK), anti-
phospho-p38MAPK (9211S, Cell Signaling, UK) anti-total-p38MAPK
(9212S, Cell Signaling, UK), Nox1 (sc-25,545, Santa Cruz, USA) and
anti-β-actin (ab8229, AbCam, UK).
2.8. Lucigenin-enhanced chemiluminescence
Lucigenin-enhanced chemiluminescence was used to assess ROS
production in rat mesenteric arteries and VSMCs stimulated with aldo-
sterone (10−7 mol/L, 30 min; Sigma, UK). In some experiments, cells
were pre-incubated for 30 min with ML171 (10−6 mol/L; Tocris, UK).
After stimulation, cells were rinsed with ice-cold PBS and harvested inWKY SHRSP
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Fig. 3.Vascular collagen expression inWKYand SHRSP rats.Mean quantiﬁcation by Image J anal
III ratio (c) assessed by picrosirius red staining analysed under polarised light. Representativ
polarised light microscopy (d). Scale bar (−) represents 200 μM. Bars represent the mean ± SROS phosphate buffer (5 × 10−2 mol/L KH2PO4, 10−2 mol/L EGTA, 1.5
× 10−1 mol/L Sucrose). NADPH (10−4 mol/L) was added to the suspen-
sion containing lucigenin (5 × 10−6 mol/L). Luminescence was mea-
sured before and after addition of NADPH. A buffer blank was
subtracted from each reading. Results are expressed as a fold change
in relative light units (RLU) per microgram of protein, as measured by
the DC assay (Bio-Rad, UK).
2.9. Quantitative real-time polymerase chain reaction (PCR)
Quantitative real-time Polymerase Chain Reaction (Applied
Biosystems) was used to analyze mRNA expression in rat mesenteric
arteries; data are expressed as target gene/18 s housekeeping gene.
Transcript expression in rat VSMCs was normalised to GAPDH,
using Qiagen QuantiTech primer assays (Qiagen, UK). Relative gene
expression was calculated by 2ΔΔCt method, and the results were re-
ported as arbitrary units relative to the control conditions. Primers
were designed using Primer3 software with sequences as shown in
Table 1.
2.10. Measurement of vascular hydrogen peroxide (H2O2) production
The production of H2O2 in vascular tissue homogenate and VSMC ly-
sate was measured using the horseradish peroxidase-linked Amplex
Red™ ﬂuorometric assay (Life Technologies, Paisley, UK) according to
manufacturer's instructions.
2.11. Statistical analysis
All data are expressed as mean ± SEM unless otherwise indicated.
Statistical comparisons of parameters between groups were made byWKY SHRSP
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ysis of percentage of collagen type I (a), collagen type III (b), collagen type I to collagen type
e images of WKY and SHRSP vessels stained with picrosirius red under bright-ﬁeld and
EM (n= 4–6 per group). *P b 0.05, **P b 0.001 vs WKY.
114 A.P. Harvey et al. / Life Sciences 179 (2017) 110–119student's t-test, 1- way and 2-way ANOVA followed by Bonferroni post-
hoc tests as appropriate. P b 0.05was considered statistically signiﬁcant.
Repeated measures ANOVA was used for comparison of groups within
vascular reactivity studies. Data analysiswas conducted usingGraphPad
Prism 5.0 (GraphPad Software Inc., San Diego, CA).3. Results
3.1. Elevated blood pressure is associated with increased plasma aldoste-
rone and galectin-3 levels in SHRSP rats
SHRSP rats had lower body weight (279.2± 9.8 g vs 353.5± 4.1 g, P
b 0.001) and increased systolic blood pressure (183.8 ± 5.2 mm Hg vs
123.5 ± 2.1 mm Hg P b 0.001) compared to WKY rats. Analysis of plas-
ma revealed elevated levels of aldosterone (99.5 ± 19.2 pg/mL vs 20.8
± 5.3 pg/mL, P b 0.05) and the pro-ﬁbrotic marker galectin-3 (233.8
± 23.5 pg/mL vs 153.7 ± 25.1 pg/mL, P b 0.05) in SHRSP rats versus
WKY rats. CA did not reduce blood pressure in either WKY (121.8 ±
11.02 mm Hg vs CA: 136.1 ± 10.32 mm Hg) or SHRSP (187.4 ±
7.53 mm Hg vs CA: 208.6 ± 3.76 mm Hg).a
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phosphorylated p66Shc (c). Data are expressed as mean ± SEM, corrected to α-tubulin expres3.2. Vascular function and mechanics are altered in SHRSP rats
Rat mesenteric arteries were studied by wire and pressure
myography to assess endothelial function, vascular contractility and
structural and mechanical properties. Hypertensive animals displayed
altered vascular function characterised by hypercontractility and, in-
creased sensitivity and maximal contractile response to phenylephrine
(Fig. 1a). As previously demonstrated [21–23], endothelium-dependent
vasorelaxation to acetylcholine was impaired in SHRSP rats (Fig. 1b).
Endothelium-independent vasorelaxation was not altered in SHRSP
rats (Supplemental Fig. 1). Vascular stiffness was increased in SHRSP
rats as demonstrated by a leftward shift in the stress-strain curve (Fig.
1c), conﬁrming previous ﬁndings [22]. Vascular media-lumen ratio
and cross sectional areawere not signiﬁcantlymodiﬁed in SHRSP versus
WKY rats (Fig. 1d, Supplemental Fig. 2).
3.3. Vascular hypercontractility involves MR, Nox1 and Rac1/2 in SHRSP
rats
To assess whether vascular dysfunction in SHRSP is related to MR-
mediated effects, vessels were pre-incubated with the MR antagonist,b
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116 A.P. Harvey et al. / Life Sciences 179 (2017) 110–119eplerenone, which reduced the hypercontractile response to phenyl-
ephrine in SHRSP rats (Fig. 2a). Rac is an established cytosolic regulator
of Nox activity. The involvement of Nox and Rac1/2 in hypertension-as-
sociated hypercontractility was assessed by pre-incubating vessels with
the Rac1/2 inhibitor, EHT1864 (Fig. 2b) or the Nox1 inhibitor, ML171
(Fig. 2c). Both EHT1864 and ML171 attenuated hypercontractility in
SHRSP vessels.3.4. Vascular extracellularmatrix remodeling and inﬂammatorymarker ex-
pression are increased in SHRSP rats
Increased vascular stiffness in hypertensive rats was associat-
ed with increased collagen Type I to Type III ratio (Fig. 3), in-
creased vascular ﬁbronectin (Fig. 4a), TGFβ (Fig. 4b) protein
expression and p66Shc activation (Fig. 4c). In addition, transcript
expression of matrix metalloproteinase (MMP)2 (Fig. 5a) and
MMP9 (Fig. 5b) was elevated in hypertensive animals. Expression
of pro-inﬂammatory molecules, RANTES (Fig. 5c) and MCP-1
(Fig. 5d) was higher in vessels from SHRSP versus normotensive
WKY rats.a
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b 0.05, ††P b 0.01 vs SHRSP vehicle. CA = canrenoic acid.3.5. Vascular redox proﬁle is altered in SHRSP rats
Mesenteric arteries from SHRSP displayed elevated levels of Nox1
transcript level (Fig. 6a). Expression of the other Nox isoforms and sub-
unitswas not altered in SHRSP (Supplementalﬁgs. 3a-f). Elevated levels
of Nox1 were associated with an increase in NADPH-dependent ROS
generation and nitrotyrosine levels (Fig. 6b, c) and decreased levels of
H2O2 (Fig. 6d).3.6. MR blockade normalises pro-inﬂammatory and pro-ﬁbrotic vascular
signaling in SHRSP rats
To determine whether MR blockade in vivo inﬂuences the pro-in-
ﬂammatory and pro-ﬁbrotic vascular phenotype in SHRSP, a group of
WKY and SHRSP rats were administered the MR blocker CA (10 mg/
kg/day) in drinking water. In aortas of CA-treated SHRSP, activation of
pro-inﬂammatory and pro-ﬁbrotic signaling molecules p66Shc (Fig.
7a) and p38MAPK (Fig. 7b) was reduced and increased expression of
Nox1 was prevented (Fig. 7c, Supplemental Fig. 4a). Collagen I mRNA
expression was signiﬁcantly increased in SHRSP, a phenomenon thatb
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117A.P. Harvey et al. / Life Sciences 179 (2017) 110–119was prevented by CA treatment (Fig. 7d). CA did not inﬂuence ﬁbronec-
tin expression inWKY or SHRSP rats (Supplemental Fig. 4b). Collagen III
mRNA level was not altered in SHRSP and unaffected by CA (Supple-
mental Fig. 4c).3.7. Aldosterone-induced ROS production is Nox1-dependent in VSMCs
To further investigate the association between aldosterone and
Nox1,we examined VSMCs fromWKYand SHRSP stimulatedwith aldo-
sterone. Aldosterone induced an increase in Nox1 expression in WKY,
an effect that was ampliﬁed in SHRSP VSMCs (Fig. 8a). Aldosterone-in-
duced ROS production in WKY and SHRSP VSMCs was prevented by
ML171 (Fig. 8b). ML171 normalised aldosterone-induced H2O2 produc-
tion inWKY VSMCs whilst SHRSP VSMCs displayed elevated basal H2O2
production, which was not enhanced with aldosterone or altered by
ML171 (Fig. 8c).3.8. Aldosterone-induced vascular signaling is blunted in Nox1-/y mice
A role for aldosterone andNox1 in vascularﬁbrosis was further eval-
uated by studying aldosterone-infused wild-type and Nox1-/y mice. Al-
dosterone stimulated expression of ﬁbronectin and the pro-ﬁbrotic
marker PAI-1 in vessels from wild-type but not from Nox1-deﬁcient
mice (Fig. 9).a
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Findings from our study demonstrate that in SHRSP 1) elevated
blood pressure is associatedwith increased levels of plasma aldosterone
and galectin-3, vascular stiffness, arterial ﬁbrosis and inﬂammation, 2)
vascular hypercontractility and pro-inﬂammatory and pro-ﬁbrotic sig-
naling is ameliorated by MR blockade and Nox1 inhibition, and 3) aldo-
sterone-mediated signaling and vascular ﬁbrosis is partially Nox1-
dependent. Together our data suggest a role for aldosterone/MR-medi-
ated Nox1 activation in vascular damage and dysfunction in SHRSP. We
also identify a novel signaling pathway involving p66Shc throughwhich
aldosterone-MR may inﬂuence vascular ﬁbrosis.
SHRSP rats are characterised by severe hypertension and associated
endothelial dysfunction and vascular damage. Exact molecular mecha-
nisms contributing to these processes remain unclear but aldosterone
may play a role. Previous studies demonstrated that plasma aldosterone
is increased in SHRSP [24], similar to what we observed in our study.
Moreover, MR blockers reduce vascular damage without effects on
blood pressure in SHRSP on normal diet [19,25] and as demonstrated
in our study, MR blockade improved vascular dysfunction and amelio-
rated pro-inﬂammatory andproﬁbrotic signaling in SHRSP. Ourﬁndings
are in line with earlier studies, which showed antiﬁbrotic effects of MR
antagonists in SHRSP [19,25].
Aldosterone induces ﬁbrosis, which may contribute to vascular re-
modeling in hypertension. Increasing evidence indicates a role for
galectin-3 in cardiovascular ﬁbrosis and cardiac dysfunction and levelsCtr
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Fig. 9. Aldosterone-induced vascular pro-ﬁbrotic signaling is blunted in Nox1 deﬁcient
mice. Aldosterone infusion (3 × 10−4 mol/L/kg/day) for 4 weeks increased protein
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deﬁcient mice. Bars represent the mean ± SEM (n = 6 per group). *P b 0.05 vs wild-
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118 A.P. Harvey et al. / Life Sciences 179 (2017) 110–119of this biomarker are now being used clinically as a predictor of heart
failure [26]. In the cardiovascular system galectin-3 has been implicated
in the development of ﬁbrosis where galectin-3 infusion increases car-
diac collagen type I:type III ratio in rats [27] and recombinant galectin-
3 inducesﬁbroblast proliferation and collagen synthesis in vitro. The im-
portance of galectin-3 in the development of aldosterone-mediated ﬁ-
brosis has been highlighted by the observation that mice lacking
galectin-3 are protected against aldosterone-induced elevation in colla-
gen expression in theheart [28] and aorta [4]. In rat VSMCs, over expres-
sion of galectin-3 enhanced aldosterone-induced collagen 1 synthesis,
whereas spironolactone or modiﬁed citrus pectin (galectin-3 inhibitor)
reversed these effects [4]. Itmay be possible that aldosterone stimulates
production of galectin-3, since increased plasma levels of galectin-3 in
patients with primary hyperaldosteronism were normalised following
adrenalectomy [29]. In our study, plasma levels of galectin-3were close-
ly associated with hyperaldosteronism and vascular dysfunction and ﬁ-
brosis. At themolecular level, increased expression of vascular collagen,
ﬁbronectin, TGFβ, MMPs, RANTES and MCP-1, together with activationof p66Shc in SHRSP rats, supports the pro-ﬁbrotic and pro-inﬂammato-
ry vascular phenotype in hypertension.
To further support a proﬁbrotic role of aldosterone-MR in SHRSP, we
previously showed that MR blockade with eplerenone prevents vascu-
lar remodeling and cardiac ﬁbrosis [19]. Others demonstrated that
spironolactone attenuates vascular ﬁbrosis in cerebral arteries in
SHRSP [25]. Our results here support these previous studies, since in-
creased mRNA expression of collagen I in SHRSP, was normalised in
mice treated with MRA. Of note, although collagen I expression was in-
creased at the gene level, it was not signiﬁcantly increased at the protein
level and may relate, at least in in part, to possible degradation by
MMPs. Supporting this notion are our ﬁndings that vascular mRNA ex-
pression of MMP2 and MMP9 was increased in SHRSP. Similar MMP
ﬁndings have been observed by others in SHRSP [30]. Although CA
prevented an increase in collagen expression in SHRSP, it did not inﬂu-
ence ﬁbronectin expression. Reasons for this may relate to the relatively
low dose of MRA used. We treated rats with 10 mg/kg/day, whereas
other studies usedMRblockers at higher doses [19,25]. Perhaps a higher
dose would have had greater antiﬁbrotic effects in our model.
SHRSP rats had elevated levels of phosphorylated p66Shc, an impor-
tant redox-sensitive signalingmolecule that has been implicated in car-
diovascular aging, vascular injury and renal dysfunction [31–34]. MR
blockade prevented activation of vascular p66Shc in SHRSP, indicating
an important role for p66Shc in aldosterone-MR signaling in vascular
tissue. To our knowledge these are theﬁrst studies suggesting that aldo-
sterone signals through p66Shc in vascular cells and support those in
kidney cells, where aldosterone-induced epithelial-to-mesenchymal
transition in renal proximal tubular cells was found to involve p66Shc
[34]. Our ﬁndings unravel a potential new signaling pathway through
which aldosterone-MR signals.
Molecularmechanisms underlying the vascular phenotype in SHRSP
and the role of aldosterone in these processes remain elusive, but oxida-
tive stress may be important. Aldosterone inﬂuences redox-sensitive
signaling in vascular smoothmuscle cells and stimulates Nox1 to induce
generation of ROS [16]. In our study, expression of vascular Nox1, but
not other Nox isoforms or Nox subunits, was increased. Inhibition of
Nox1 and its regulator Rac1/2 with ML171 and EHT1864 respectively,
restored hypercontractility suggesting a functional link between Nox1
upregulation and impaired vascular function in hypertension. Because
of the vasoprotective effects of eplerenone and ML171 in SHRSP, we
questioned whether aldosterone actions may be mediated through
Nox1-dependent processes in this model.
Increased vascular expression of Nox1 was associated with in-
creased levels of vascular O2•- and ONOO−, which may contribute to ox-
idative stress-induced vascular injury. Whereas generation of O2•− and
ONOO−was increased in SHRSP, levels of vascular H2O2 were reduced.
Since H2O2 may act as an endothelium-derived relaxing factor, de-
creased bioavailability of this ROS may lead to reduced vasorelaxation
and increased contraction [35,36]. To explore the putative relationship
between aldosterone and Nox1 in SHRSP we studied cultured VSMCs
from SHRSP and WKY. Aldosterone induced expression of Nox1 in
WKY with an ampliﬁed effect in SHRSP. Nox1 inhibition attenuated al-
dosterone-stimulated ROS generation in VSMCs from both normoten-
sive and hypertensive rats. In contrast to ﬁndings in intact arteries,
SHRSP VSMCs produced more H2O2 than WKY VSMCs. Reasons for
this may relate to the fact that H2O2 production is differentially regulat-
ed with variable functional effects in endothelial cells and in VSMCs. In
particular, in endothelial cells, H2O2 acts as a vasodilator, whereas in
VSMCs H2O2 may promote vasoconstriction [35,36]. Hence the diver-
gent ﬁndings in our study between isolated VSMC versus intact arteries
likely reﬂects the contribution of endothelial cells in whole vessels. Our
ﬁndings that ML171 inhibits aldosterone effects, suggest a role for Nox1
in aldosterone-mediated vascular actions. The observation that ML171
reduced NADPH-dependent ROS but not H2O2 production in SHRSP
VSMCs may suggest that the elevated H2O2 levels in these cells are
Nox1-independent.
119A.P. Harvey et al. / Life Sciences 179 (2017) 110–119To further elucidate the relationship between aldosterone, Nox and
vascular ﬁbrosis, in vivo, aldosterone-infused Nox1-deﬁcient mice
were studied.Whereas vascular content ofﬁbronectin and PAI-1was in-
creased in aldosterone-infused wild-type mice, this was not evident in
mice lacking Nox1. These ﬁndings suggest an important role for Nox1
in aldosterone-mediated vascular changes and support our ﬁndings in
SHRSP and cultured VSMCs.
5. Conclusions
Aldosterone and oxidative stress may be important regulators of
vascular changes associated with hypertension. Our data suggest that
aldosterone/MR-induced vascular dysfunction and arterial remodeling
involve Nox1-mediated redox-p66Shc signaling. We deﬁne a novel mo-
lecular mechanism underlying vascular changes in hypertension.
Targeting MR and Nox1 may have vasoprotective effects.
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